Rhythm Pharmaceuticals, Inc. Common Stock
RYTM Real Time Price USDRecent trades of RYTM by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by RYTM's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
RYTM Revenue by Segment or Geography
No Revenue by Segment data for this ticker
No Revenue by Geography data for this ticker
New patents grants
-
Patent Title: Peptide compositions Sep. 03, 2024
-
Patent Title: Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers Jul. 18, 2023
-
Patent Title: Pharmaceutical compositions Sep. 28, 2021
-
Patent Title: Method of treating melanocortin-4 receptor pathway-associated disorders Mar. 30, 2021
-
Patent Title: Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers Mar. 23, 2021
-
Patent Title: Peptide compositions Dec. 08, 2020
-
Patent Title: Peptide compositions Feb. 05, 2019
-
Patent Title: Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers Jan. 01, 2019
-
Patent Title: Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers Dec. 19, 2017
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to RYTM
Number of mentions of RYTM in WallStreetBets Daily Discussion
Recent picks made for RYTM stock on CNBC
ETFs with the largest estimated holdings in RYTM
|
Shareholder
|
Shares Held
|
|---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view RYTM Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.